MedTrace Logo

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

NCT01953874 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2018-02-28

Study results available
· View outcomes & findings →

Summary

The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF. The study will also assess changes in functional parameters, biomarkers, quality of life (QOL), and sleep.

Conditions

  • Acute Decompensated Heart Failure
  • Sleep Disordered Breathing

Interventions

DEVICE

MV ASV

Minute ventilation-targeted servo-ventilation therapy.

DRUG

Optimized Medical Treatment

Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated

Sponsors & Collaborators

  • ResMed Foundation

    collaborator OTHER

  • ResMed

    lead INDUSTRY

Principal Investigators

  • Christopher O'Connor, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01953874 on ClinicalTrials.gov